Washington Hospital Center, Washington, DC, USA.
J Clin Microbiol. 2010 Sep;48(9):3258-62. doi: 10.1128/JCM.02529-09. Epub 2010 Jul 14.
While the increasing importance of methicillin-resistant Staphylococcus aureus (MRSA) as a pathogen in health care-associated S. aureus pneumonia has been documented widely, information on the clinical and economic consequences of such infections is limited. We retrospectively identified all patients admitted to a large U.S. urban teaching hospital between January 2005 and May 2008 with pneumonia and positive blood or respiratory cultures for S. aureus within 48 h of admission. Among these patients, those with suspected health care-associated pneumonia (HCAP) were identified using established criteria (e.g., recent hospitalization, admission from nursing home, or hemodialysis). Subjects were designated as having methicillin-resistant (MRSA) or methicillin-susceptible (MSSA) HCAP, based on initial S. aureus isolates. Initial therapy was designated "appropriate" versus "inappropriate" based on the expected susceptibility of the organism to the regimen received. We identified 142 patients with evidence of S. aureus HCAP. Their mean (standard deviation [SD]) age was 64.5 (17) years. Eighty-seven patients (61%) had initial cultures that were positive for MRSA. Most ( approximately 90%) patients received appropriate initial antibiotic therapy (86% for MRSA versus 91% for MSSA; P = 0.783). There were no significant differences between MRSA and MSSA HCAP patients in mortality (29% versus 20%, respectively), surgery for pneumonia (22% versus 20%), receipt of mechanical ventilation (60% versus 58%), or admission to the intensive care unit (79% versus 76%). Mean (SD) total charges per admission were universally high ($98,170 [$94,707] for MRSA versus $104,121 [$91,314]) for MSSA [P = 0.712]). Almost two-thirds of patients admitted to hospital with S. aureus HCAP have evidence of MRSA infection. S. aureus HCAP, irrespective of MRSA versus MSSA status, is associated with significant mortality and high health care costs, despite appropriate initial antibiotic therapy.
虽然耐甲氧西林金黄色葡萄球菌(MRSA)作为医院获得性金黄色葡萄球菌肺炎的病原体的重要性日益增加,但有关此类感染的临床和经济后果的信息有限。我们回顾性地确定了 2005 年 1 月至 2008 年 5 月期间在美国一家大型城市教学医院住院的所有患者,这些患者在入院后 48 小时内血或呼吸道培养出金黄色葡萄球菌阳性。在这些患者中,根据既定标准(例如最近住院、从疗养院或血液透析病房入院)确定了疑似医院获得性肺炎(HCAP)患者。根据初始金黄色葡萄球菌分离物,将患者指定为耐甲氧西林金黄色葡萄球菌(MRSA)或甲氧西林敏感金黄色葡萄球菌(MSSA)HCAP。根据所接受的方案,将初始治疗指定为“适当”或“不适当”,以评估该生物体对方案的预期敏感性。我们发现了 142 例金黄色葡萄球菌 HCAP 患者。他们的平均(标准差[SD])年龄为 64.5(17)岁。87 例(61%)患者的初始培养物对 MRSA 呈阳性。大多数(约 90%)患者接受了适当的初始抗生素治疗(MRSA 为 86%,MSSA 为 91%;P = 0.783)。MRSA 和 MSSA HCAP 患者在死亡率(分别为 29%和 20%)、肺炎手术(分别为 22%和 20%)、机械通气(分别为 60%和 58%)或入住重症监护病房(分别为 79%和 76%)方面无显著差异。每次住院的平均(SD)总费用普遍较高(MRSA 为 98170 美元[94707 美元],MSSA 为 104121 美元[91314 美元])[P = 0.712])。将近三分之二因 HCAP 住院的金黄色葡萄球菌患者有证据表明存在 MRSA 感染。金黄色葡萄球菌 HCAP ,无论 MRSA 与 MSSA 状态如何,尽管采用了适当的初始抗生素治疗,但仍与显著的死亡率和高昂的医疗费用相关。